Global menu

Our global pages

Close

People search

Filter by:
 
Magdalena Anna Kotyrba-Hagenmaier, Principal Associate

Magdalena Anna Kotyrba-Hagenmaier

Principal Associate

Rechtsanwältin

Languages

German, English, Polish

Practice areas

  • Commercial agreements
  • Competition, EU and Trade
  • Health and life sciences
  • Intellectual property
  • Regulatory investigations and enforcement
  • Technology

Practice notes

Magdalena Anna Kotyrba-Hagenmaier is a Principal Associate in Eversheds Sutherland’s Munich office and member both of its IP practice and the Health and Life Sciences Sector Group.

Her scope of activity includes negotiating, protecting and enforcing IP rights for her clients from a wide range of industry, as well as advising clients from the life sciences industry (pharmaceuticals, medical devices, cosmetics, food, chemicals).

As member of our Health & Life Sciences Sector Group Magdalena advises companies from the life sciences industry on several topics, including contractual as well as regulatory matters, topics related to clinical and other trials, as well as questions related to healthcare compliance. She also advices her clients on questions in connection with manufacturing and distribution of life sciences products. Furthermore, she focuses on technology transfer related matters and convergence topics, such as health-apps.

An important part of Magdalena’s activity is advising clients on topics related to R&D in general regarding the creation and protection of her clients’ IP rights. She has specific experience with advising on and negotiation of IP rights resulting from trials and research collaborations between industry partners but also between the industry and universities or other research institutions. Clients appreciate her expertise with granting rights to use and exploitation of IP rights such as licensing, technology transfer, contract research and in general on IP-topics of all kinds.

Before joining Eversheds Sutherland, Magdalena worked for a boutique law firm focusing on pharmaceutical and competition law as well as in-house for an international pharmaceutical company in the area of R&D and healthcare compliance.

Magdalena is recommended by Legal500 Germany for health. Furthermore, she is recommended for Intellectual Property Law by Best Lawyers/Handelsblatt in the young talent category "Ones to Watch".

Magdalena's recent experience:

  • US based technology group on the market access and CE-certification of a testing device in the European Union
  • Otsuka on licensing agreements with global pharmaceutical company Mylan regarding the market access and commercialization of Deltyba™ (delamanid) for the treatment of multidrug-resistant tuberculosis (MDR-TB) in low- and middle-income countries
  • UK based international pharmaceutical group on the defence of marketing campaigns attacked by a competitor on a multi-jurisdictional level
  • US based international group in the area of motion control technologies on EU medical devices related topics and on self-tests for laymen
  • Germany based biotech company developing and manufacturing active immunotherapies for patient-specific approaches to the treatment of diseases on different IP topics (IP transfer agreements, licensing, employee inventions)
  • Owens & Minor on its sell of Movianto from a regulatory perspective (marketing authorizations and other licenses required by the German Medicinal Product Act)
  • An international generic drug company on the defence of marketing authorizations being challenged by the originator pharmaceutical company due to alleged IP infringements in the generics marketing authorization application
  • German research institution on IP and regulatory related topics in collaborations and trial agreements with research companies
  • INEOS on the production of disinfectants in response to the Covid-19 crisis
  • Several US and Europe based medical device manufacturers on IP related topics in pre- and post-CE-marketing trials
  • Otsuka on the First-of-its-kind global Collaboration between the Gates Foundation and Johnson & Johnson, GSK and Evotec to develop transformative treatment regimens for Tuberculosis
  • Medical devices distributor commercializing its Japanese parent company’s medical app to healthcare institutions in Europe, the Middle East and Africa
  • European based generics company on license agreements and collaborations
  • An US based medical device manufacturer on the negotiations of clinical trial agreements and post-CE trial agreements with universities or other German research institutions
  • An international pharmaceutical company on legal matters in connection with market access programs by several national regulators regarding pharmaceuticals
  • International research company on R&D-collaborations and negotiations with research institutes and universities on development and licensing of new technologies
  • Otsuka on a licensing agreement with Russian pharmaceutical company R-Pharm to commercialize Deltyba™ (delamanid) for the treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB) in the Russian Federation and the Commonwealth of Independent States (CIS)

Featured article

Deutsches Profil

The Legal 500 - The Clients Guide to Law Firms

Print Friendly and PDF

© Eversheds Sutherland 2021. All rights reserved. Eversheds Sutherland is a global provider of legal and other services operating through various separate and distinct legal entities.

Eversheds Sutherland is the name and brand under which the members of Eversheds Sutherland Limited (Eversheds Sutherland (International) LLP and Eversheds Sutherland (US) LLP) and their respective controlled, managed and affiliated firms and the members of Eversheds Sutherland (Europe) Limited (each an "Eversheds Sutherland Entity" and together the "Eversheds Sutherland Entities") provide legal or other services to clients around the world. Eversheds Sutherland Entities are constituted and regulated in accordance with relevant local regulatory and legal requirements and operate in accordance with their locally registered names. The use of the name Eversheds Sutherland, is for description purposes only and does not imply that the Eversheds Sutherland Entities are in a partnership or are part of a global LLP. The responsibility for the provision of services to the client is defined in the terms of engagement between the instructed firm and the client.